Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?
Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?
复制标题
肥胖和内源性大麻素系统:CB1 拮抗剂治疗肥胖症还有未来吗?
DOI:
10.1007/s13679-012-0031-x
复制
发表时间:
2012
影响因子:
8.8
通讯作者:
F. R. Fonseca
中科院分区:
文献类型:
--
作者:
A. Serrano;F. Pavón;J. Suárez;M. Romero‐Cuevas;E. Baixeras;P. Goya;F. R. Fonseca
The current epidemic of obesity in western countries is being worsened by the lack of effective pharmacotherapies. The apparent success of a central nervous system-acting cannabinoid CB1 receptor antagonist-based treatment for obesity was hampered by the appearance of psychiatric side effects in certain patients. These adverse effects forced its withdrawal from the market. However, the discovery that the main beneficial metabolic effects of cannabinoid CB1 receptor antagonists were derived of its activity in peripheral tissues, including the adipose tissue, opened the possibility of rescuing this type of therapy. This goal might be achieved by differential medicinal chemistry approaches. The present review examines these options that include peripheral-restricted cannabinoid CB1 receptor antagonists, dual ligands and combinatorial therapies using sub-effective doses of CB1 receptor antagonists that might be devoid of side effects.
登录
查看更多内容
DOI:
--
发表时间:
1997
期刊:
The Journal of pharmacology and experimental therapeutics
影响因子:
--
作者:
Breivogel,CS;Sim,LJ;Childers,SR
通讯作者:
Childers,SR
影响因子:
2.7
作者:
LoVerme J;Duranti A;Tontini A;Spadoni G;Mor M;Rivara S;Stella N;Xu C;Tarzia G;Piomelli D
通讯作者:
Piomelli D
DOI:
--
发表时间:
2003
期刊:
American journal of physiology. Regulatory, integrative and comparative physiology
影响因子:
--
作者:
A. Thorpe;M. Mullett;Chuanfeng Wang;C. Kotz
通讯作者:
A. Thorpe;M. Mullett;Chuanfeng Wang;C. Kotz
影响因子:
15.9
作者:
Tam, Joseph;Vemuri, V. Kiran;Kunos, George
通讯作者:
Kunos, George
影响因子:
56.9
作者:
DEVANE, WA;HANUS, L;MECHOULAM, R
通讯作者:
MECHOULAM, R